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ABSTRACT
This protocol describes a cohort study comparing the risks of mortality and serious self-harm (suicide
or near-fatal deliberate self-harm) between adults with depression prescribed mirtazapine, a selective
serotonin reuptake inhibitor (SSRI), amitriptyline, or venlafaxine. The study is set within English
primary care electronic health records from the Clinical Practice Research Datalink (CPRD) and covers
the period 01 January 2005 – 30 November 2018. The study described uses an active comparator
new user design: patients are included if they are first prescribed an SSRI before being prescribed
mirtazapine, a different SSRI, amitriptyline, or venlafaxine as their second antidepressant. Patients
are followed from the initial prescription for the second antidepressant until an outcome (mortality,
serious self-harm), end of CPRD follow-up, or study end. Inverse probability of treatment weighting is
used to account for confounding variables. The protocol was submitted to the CPRD Independent
Scientific Advisory Committee for review and was approved in November 2019 (protocol number
19_241).
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A. Study Title
A cohort study examining the association between
mirtazapine and mortality risk in adults with a
diagnosis of depression
B. Lay Summary
Mirtazapine is a treatment for depression in adults.
Some studies have found a link between
mirtazapine and increased risk of death compared
to other antidepressants. However, other factors
may make this link seem stronger than it is. For
example, doctors may prescribe mirtazapine to
terminally ill patients as it can increase appetite and
promote sleep.
The aim of this study is to better understand the
relationship between mirtazapine and risk of death.
We will look at the risk of specific causes of death,
including heart disease and cancer. We will also look
at whether there is a link between mirtazapine and
attempted suicide.
We will use data from the Clinical Practice Research
Datalink (CPRD) for this study. The dataset will
include anonymised electronic medical records from
general practices and hospitals, as well as
anonymised death records. We will compare a group
of patients taking mirtazapine with groups of
patients taking other antidepressants. The groups
will be made up of adult patients with depression.
We will compare the risk of death or attempted
suicide between the groups. Risk factors such as
age, sex, and other health conditions will be taken
into account in the analyses.
The study will provide further information about
whether there is a link between mirtazapine and risk
of death or attempted suicide. This will include
whether there is a link with particular causes of
death. This will be important information for doctors
and patients when considering suitable
antidepressant treatment.
C. Technical Summary
Previous studies have found an association between
the antidepressant mirtazapine and increased risk
of mortality. Further research is needed to confirm
this association and to examine specific causes of
death. The proposed study will compare mirtazapine
to other antidepressants and investigate cause-
specific mortality, controlling for relevant
confounding.
We will perform a cohort study using the active-
comparator new user design, selecting patients
prescribed antidepressants between 1st January
2005 and 30th November 2018. Linked CPRD
primary care data, Office for National Statistics
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(ONS) mortality data, and Hospital Episode Statistics
(HES) admitted patient care data will be used.
The study population will comprise adult patients
diagnosed with depression whose first
antidepressant was a selective serotonin reuptake
inhibitor (SSRI) and who were subsequently
prescribed mirtazapine, venlafaxine, amitriptyline, or
a different SSRI. Follow-up will start from the date of
starting the new antidepressant.
There will be five exposure groups: those who
switched to mirtazapine, those who started
mirtazapine while continuing the original SSRI, and
those who switched to venlafaxine, amitriptyline, or
a different SSRI.
The outcomes will be all-cause and cause-specific
mortality, and suicide/near-fatal deliberate self-
harm. Cause-specific mortality will include
cardiovascular disease, cancer, and the most
common causes of death found within the study
population. Date and cause of death will be taken
from the ONS mortality dataset while near-fatal
deliberate self-harm will be defined using a
combination of primary care and HES data.
We will account for confounding factors including
demographic characteristics, lifestyle factors, drug
exposures, and comorbidities. These will be used to
estimate propensity scores for each of the
comparator drugs compared with mirtazapine.
Baseline characteristics and the most frequent
causes of death will be summarised. Survival
analysis using Cox and Fine-Gray (competing risk)
regression will be performed, accounting for
propensity scores.
D. Outcomes to be Measured
All-cause mortality; cause-specific mortality
(including cardiovascular disease and cancer);
suicide or near-fatal deliberate self-harm.
E. Objectives, Specific Aims and Rationale
Objective: to examine the association between the
antidepressant mirtazapine and risks of mortality
and suicidal behaviour by exploring specific causes
of death in a cohort of patients with depression.
Mortality rates for patients taking mirtazapine and
patients taking other antidepressants will be
compared.
Specific aims:
(1) To describe and compare the characteristics of
patients prescribed mirtazapine compared to
alternative antidepressants
(2) To estimate rates of all-cause mortality, cause-
specific mortality, and suicide/near-fatal
deliberate self-harm in those prescribed
mirtazapine and alternative antidepressants
(3) To test the hypothesis that the rate of all-cause
mortality differs between those taking
mirtazapine and those taking alternative
antidepressants
(4) To test the hypotheses that rates of specific
causes of death differ between those taking
mirtazapine and those taking alternative
antidepressants using survival analysis with
competing risks
(5) To test the hypothesis that the rate of
suicide/near-fatal deliberate self-harm differs
between those taking mirtazapine and those
taking alternative antidepressants using
survival analysis with competing risks
Rationale: mirtazapine has been associated with an
increased risk of all-cause mortality(1). This
association could reflect a direct effect of the drug
(e.g. increased risk of suicide) or confounding
factors that influence choice of antidepressant. This
study will generate additional evidence about the
comparative risk of mortality, cause-specific
mortality, and suicide/near-fatal deliberate self-
harm in patients taking mirtazapine compared with
other antidepressants. Differences between the
treatment groups will be summarised and
accounted for in analyses.
F. Study Background
This study will examine the association between
mirtazapine, mortality, and self-harm in patients with
depression. Mirtazapine is licensed to treat
depression in adults and has similar efficacy to other
antidepressants(2). The tolerability of mirtazapine is
also similar to other antidepressants, although the
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typical side effects differ(2,3). Mirtazapine was the
7th most frequently prescribed antidepressant
between 2000-2011 in a UK cohort of patients with
depression(4). Openly-available English prescribing
data(5) show the number of mirtazapine
prescriptions is increasing over time, with
8,938,362 prescriptions issued in the community in
2018 compared with 2,437,500 in 2008(6).
Observational research set within UK primary care
has highlighted an increased risk of all-cause
mortality in patients prescribed mirtazapine
compared with other antidepressants(1,7). These
studies also demonstrated an increased risk of
suicide and attempted suicide/self-harm associated
with mirtazapine(1,4). While the increased mortality
could reflect this increased risk of suicide, additional
factors may also contribute. As different
antidepressants have similar efficacy, side effects
and individual patient characteristics may influence
choice of antidepressant(3). If so, factors influencing
choice of antidepressant may confound the
relationship between mirtazapine and mortality.
Clinicians may preferentially prescribe mirtazapine
to certain patient populations because of its positive
effects on appetite(8–10) and sleep(11). For
instance, the British National Formulary(12)
suggests prescribing mirtazapine to patients with
sleep disturbance in depression (chapter 4.1.1). It is
also possible mirtazapine is preferentially
prescribed to treat depression in patients on the
palliative care pathway(13–16). Studies need to
account for the possibility of such confounding.
To better understand the association between
mirtazapine and mortality it is also necessary to
explore specific causes of death. As described
above, mirtazapine may be associated with
increased risk of suicide or self-harm. In addition, as
mirtazapine has been linked to weight gain there
could be an association between mirtazapine and
deaths due to cardiovascular disease. This study will
explore the risk of deaths due to suicide,
cardiovascular disease, cancer, and other common
causes of death within the study population.
UK guidelines for the treatment of depression(17)
recommend that, where antidepressants are
prescribed, SSRIs should be prescribed in the first
instance. If ineffective or not tolerated, the
guidelines recommend switching to a "different SSRI
or a better tolerated newer-generation
antidepressant". If the patient is willing to tolerate
the increased side-effect burden, augmenting
treatment with other drugs including mirtazapine
could be considered. However, where patients have
another chronic physical health problem
mirtazapine may be preferred as the first
antidepressant over SSRIs(18). Therefore, patients
whose first antidepressant is mirtazapine are likely
to differ systematically from patients whose first
antidepressants are SSRIs. For this reason, the
current study will include patients who switch from
SSRIs to mirtazapine or one of the comparator drugs
(see below) rather than new users.
Those who switch to mirtazapine will be compared to
those who switch to a different SSRI, or to
venlafaxine or amitriptyline. The SSRI group are
included as the standard treatment group, if
prescribing according to guidelines. We are planning
to include SSRIs as a single group to avoid reducing
the sample size for the other comparison groups.
There is evidence that different SSRIs have similar
risk/benefit profiles, including similar risk of
mortality(1). The venlafaxine group are included to
represent an alternative "newer-generation
antidepressant". Amitriptyline, a tricyclic
antidepressant, is included as a comparison group
as previous studies have found an increased risk of
mortality similar to mirtazapine(1). A final
comparison will be made between those who switch
to mirtazapine and those who augment SSRI
treatment with mirtazapine. The study will be
therefore able to compare many of the common
treatment options available for treatment of
depression.
The association between mirtazapine and mortality
was highlighted in studies using the QResearch
database(1,4,7). A number of CPRD studies have
previously investigated antidepressant safety. For
example, studies report a decreased risk of
myocardial infarction associated with SSRIs(19) and
decreased risk of certain cancers associated with
tricyclic antidepressants(20). However, many
studies grouped antidepressants by antidepressant
class, with few reporting results for individual drugs.
Studies reporting results for mirtazapine
demonstrated an increased risk of significant weight
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gain(10), and a possible increased risk of
seizures(21).
G. Study Type
Descriptive (aims 1 and 2) and hypothesis testing
(aims 3 - 5).
H. Study Design
Cohort study using the active-comparator new user
design(22). Adult patients initially taking an SSRI for
depression who switch to mirtazapine or one of the
comparator drugs (see Section N) will be followed
from the date of switch until the end of drug
exposure, starting a different antidepressant, death,
leaving the cohort, or end of study period. The
outcomes will be all-cause mortality, cause-specific
mortality, and suicide/near-fatal deliberate self-
harm. We will generate propensity scores using
potential confounding variables and account for
these in analyses. We will calculate crude and age-
sex adjusted mortality rates and use survival
analysis to estimate the risk of mortality associated
with the different antidepressants compared to
mirtazapine.
This design will:
• Reduce the scale of unmeasured confounding by
ensuring exposure groups are more similar at
index date
• Avoid potential immortal time bias by defining an
equivalent index date across exposure groups
• Allow the relative timing of events to be taken into
account, defining confounders using information
recorded prior to exposure to the drug of interest
• Compare mirtazapine exposure to alternative
antidepressants rather than a 'no use' category,
providing results that are more clinically
meaningful
Mirtazapine is not recommended as the first drug
treatment for depression in adult patients:
guidelines recommend initially trying an SSRI. It is
possible that patients whose first antidepressant is
mirtazapine are systematically different from
patients initiating an SSRI as recommended. For this
reason we have chosen to start follow-up at the first
switch from SSRI, rather than first ever
antidepressant. We explored the numbers of
patients initiating mirtazapine or the comparator
drugs and found the counts were similar to the
numbers who switched.
We are planning to repeat the analysis in QResearch,
given appropriate approvals and agreements. If
successful we will combine the results by meta-
analysis as in previous studies (e.g. Vinogradova et
al. 2019 (23)).
I. Feasibility Counts
We extracted the prescription dates for SSRIs,
mirtazapine, amitriptyline, and venlafaxine from the
September 2019 CPRD dataset release. After
applying the acceptability and follow-up date criteria
described in section L, we generated the following
sample size estimates:





– a different SSRI (n=135,702)
The dataset will be limited to those with linkage to
the ONS Mortality and the HES datasets. Assuming
approximately 50% are linked, new estimates are:
• switch to mirtazapine: n=20,000
• switch to venlafaxine: n=4700
• switch to amitriptyline: n=27,500
• switch to a different SSRI: n=67,800
These represent crude estimates and do not
account for factors such as evidence of depression,
the length of time between prescriptions, or any
exposure to other antidepressants.
J. Sample Size Considerations
We estimated the power of detecting a difference in
all-cause mortality and in the rate of suicide/near-
fatal deliberate self-harm between patients
switching to mirtazapine compared to patients
switching to each of the comparator drugs.
Estimated rates were based on rates published by
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Coupland et al (all-cause mortality(1),
suicide/attempted suicide/self-harm(4)), based on
cohorts of patients aged 20-64 years old with a
diagnosis of depression.
The following Stata command was used to calculate
power, based on the estimated sample sizes from
Section I:
"power twoproportions r1 r2, alpha(0.05) n1(N1)
n2(N2)"
where r1 is the incidence rate for the comparator
drug, r2 is the incidence rate for mirtazapine, N1 is
the sample size for the comparator drug, and N2 is
the sample size for mirtazapine. This calculation
estimates power to detect a difference between two
proportions therefore does not take length of follow-
up into account.
Crude mortality rates:
• Mirtazapine 110 deaths / 10,343 person years
= 0.0106 (106 per 10,000 person years)
• Venlafaxine 73 deaths / 15,835 person years =
0.0046 (46 per 10,000 person years)
• Amitriptyline 194 deaths / 19,845 person years
= 0.0098 (98 per 10,000 person years)
• SSRIs 990 deaths / 228,233 person years =
0.0043 (43 per 10,000 person years)
The crude rates of suicide/attempted suicide/self-
harm:
• Mirtazapine 16 events / 10,343 person years =
0.0015 (15 per 10,000 person years)
• Venlafaxine 13 events / 15,835 person years =
0.0008 (8 per 10,000 person years)
• Amitriptyline 4 events / 19,845 person years =
0.0002 (2 per 10,000 person years)
• SSRIs 79 events / 228,233 person years =
0.0003 (3 per 10,000 person years)
Estimated power, all-cause mortality:
• venlafaxine vs mirtazapine: power = 0.992
• amitriptyline vs mirtazapine: power = 0.140
• SSRIs vs mirtazapine: power = 1.00
Estimated power, suicide/self-harm:
• venlafaxine vs mirtazapine: power = 0.169
• amitriptyline vs mirtazapine: power = 0.997
• SSRIs vs mirtazapine: power = 0.998
Based on the estimated counts and rates, the study
is likely to have sufficient power for many of the
comparisons. Comparisons with a smaller risk
difference may be underpowered (e.g. mirtazapine
vs amitriptyline for mortality, mirtazapine vs
venlafaxine for suicide/near-fatal deliberate self-
harm). As discussed in Section I, the feasibility
counts are likely to be overestimates. Power will be
discussed in the planned publication, and
confidence intervals will be presented with all
estimates.
If the final number of patients in the venlafaxine
group is low, we will consider using a combine
selective-noradrenaline reuptake inhibitor (SNRI)
group including venlafaxine and duloxetine.
K. Planned use of Linked Data
Date and cause of death will be determined using
the ONS mortality dataset. The definition of near-
fatal deliberate self-harm will include data from the
HES admitted patient dataset. The analysis will
account for socio-economic status using the
Townsend Score from the deprivation dataset. The
cohort will be restricted to patients at practices
contributing to the ONS mortality dataset and HES
admitted patient care dataset. Follow-up will be
censored at the end of the linkage window.
L. Definition of the Study Population
Preliminary code lists to be used throughout study
definition are available from the authors, with
further details in Appendix 1. A diagram explaining
the time windows described below has also been
provided as an appendix (Appendix 2).
Only data recorded after the up-to-standard date (an
indicator of data quality provided by CPRD) will be
included in the study. All patients will require at least
1 year of follow-up after this up-to-standard date or
joining the practice.
Study window: 1st January 2005 – 30th November
2018; this period begins the year after the patent for
mirtazapine expired (2004), when generic versions
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became available, and ends at the end of the current
HES linkage window
Eligibility window start: latest of up-to-standard date
+ 1 year, current registration date + 1 year, first
registration date + 1 year, date of turning 18 years
old, 1st January 2005
Eligibility window end: earliest of transfer out date,
last collection date, death date, prescription for a
third antidepressant, 30th November 2018
First SSRI: date of first prescription for an SSRI
during the eligibility window
Index prescription: first prescription for mirtazapine
or one of the comparator antidepressants (see
Section N) recorded after the first SSRI; index date
is the date of the index prescription
Inclusion criteria:
 Permanently registered acceptable patient AND
 Registered at a practice linked to the ONS
mortality dataset and HES admitted patient
datasets AND
 At least 0 days of follow-up (eligibility start <=
eligibility end) AND
 First prescription for an SSRI recorded after the
start of the eligibility window AND
 At least 1 prescription for mirtazapine or the
comparator drugs within the eligibility window
AND
 Index prescription is recorded after the first SSRI
and either during exposure to or less than 90
days after the end of exposure to the first SSRI
AND
 A depression Read code is recorded less than 12
months before the first SSRI prescription up to
the index prescription
Exclusion criteria:
 Age 100 years old or above at index date OR
 A prescription for any antidepressant other than
an SSRI prior to the index prescription OR
 Any previous antidepressant switch prior to index
prescription OR
 A record of bipolar disorder or schizophrenia prior
to index prescription
Follow-up: from date of index prescription to death,
starting another different antidepressant, end of
index antidepressant use (see Section N), or end of
eligibility
M. Selection of Comparison Groups
Patients will be grouped according to the
antidepressant prescribed at the index prescription.
The exposure and comparison groups will be defined
as described in Sections L and N. Each comparison
group will have an equivalent start point, i.e. patients
have to survive until starting their index
antidepressant.
N. Exposures, Outcomes and Covariates
Exposure
Exposure is defined as a prescription for mirtazapine
or one of the comparator antidepressants. The
antidepressant prescribed at the index prescription
will determine which exposure groups patients are
in. The comparator antidepressants will be:
venlafaxine, amitriptyline, and a different SSRI. A
further comparison will be made between those who
switch to mirtazapine and those who augment SSRI
treatment with mirtazapine (i.e. those who continue
to be prescribed the original SSRI after starting
mirtazapine).
As described in Section J, if numbers of patients
switching to venlafaxine are low we will consider
using a combined SNRI group (venlafaxine and
duloxetine). If numbers allow, we will group those in
the augmented treatment cohort according to the
initial SSRI and perform a subgroup analysis to
investigate possible interactions between SSRIs and
mirtazapine.
The period of exposure to a drug will be calculated
based on prescription records. The start (typically
the prescription date) and stop date of each
individual prescription will be calculated using a
published drug data preparation algorithm(24). We
will consider the exposure period as continuous
where prescription start and stop dates overlap.
To define the 'period-at-risk', a six month risk carry-
over period will be added to the stop date of
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individual prescriptions. Periods-at-risk will run from
the first prescription for the drug of interest until the
earliest of: stopping the drug + the carry-over period,
a prescription for a different antidepressant, death,
or the end of the eligibility window. The analyses will
include only one period-at-risk per patient.
The dose of each prescription will be estimated by
dividing the strength by numeric daily dose.
Fluoxetine-equivalent doses will be calculated(25).
Outcomes
All-cause mortality, cause specific-mortality, and
suicide/near-fatal deliberate self-harm(26). Cause
of death will be based on the underlying cause of
death field within the ONS dataset. Date of death will
be taken from the ONS dataset. Specific causes of
interest are: cardiovascular disease, cancer, and
suicide. Other frequent causes of death identified in
the dataset will also be analysed. A composite
outcome of suicide/near-fatal deliberate self-harm
will be defined using the primary care, HES, and ONS
mortality data: the first record in any dataset with a
relevant code will be used as the event date.
Covariates
Covariates will be included in the propensity score
models. These include likely confounding factors
and factors associated with mortality. The latter
factors are those included in the Charlson
Comorbidity Index(27) and QMortality risk prediction
algorithm(28). Covariates are listed below.
Demographic characteristics: age in index year
(taking 01 Jan to be each patient's birthday); sex
(male/female); ethnicity (most recent code prior to
index date); socio-economic status (Townsend score
quintile); practice region.
Lifestyle indicators: body mass index; smoking
status; alcohol use (non-/ former/ occasional/
moderate/ heavy drinker), 'alcohol misuse' will also
be defined.
Medication use: opioid use; glucocorticoid use; non-
steroidal anti-inflammatory drugs (NSAIDs); statins;
antipsychotics; anxiolytic medication; hypnotic
agents.
Comorbidities: depression severity (mild/ moderate/
severe); insomnia; loss of appetite; unexplained/
unintentional weight loss; epilepsy/ seizures; anxiety
(including panic disorder); personality disorder;
eating disorders; Huntington's disease; Parkinson's
disease; multiple sclerosis; hypertension;
myocardial infarction; congestive heart failure;
peripheral vascular disease; cerebrovascular
disease; angina; atrial fibrillation; venous
thromboembolism; hemiplegia; dementia; chronic
obstructive pulmonary disease (COPD); asthma;
dyspnoea; rheumatologic disease; peptic ulcer
disease; diabetes mellitus (type 1 and 2), with and
without complications; renal disease; cancer;
metastatic solid tumour; liver disease, mild and
moderate; acquired immune deficiency syndrome
(AIDS); leg ulcer; pancreatitis; poor mobility;
anaemia; intellectual disability; unplanned hospital
admission; and living in a care home.
Presence of covariates will be assessed using data
recorded on or before the index date. To define
depression severity, the depression Read codes
have been categorised according to severity, where
possible. Patients will be assigned the highest
severity in their record prior to index date. Missing
values will be imputed. To be classified as a
medication user the patient will require a
prescription for that drug within the 6 months prior
to index date. For ethnicity, body mass index,
smoking status, and alcohol use the most recent
record prior to index date will be used. Medical
conditions will be considered present at baseline if
there is a record of that condition prior to index date.
For cancer, 'recent' (record in past year) and 'ever'
categories will be used.
Other variables
A series of sensitivity analyses excluding patients
with prior records for palliative/end-of-life care, near-
fatal intentional self-harm, bipolar disorder, and
schizophrenia will be performed.
Code lists
Where possible, code lists have been sourced
through publications, clinicalcodes.org, or the
CALIBER phenotype resource(29). In some cases,
new preliminary code lists have been developed
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which will be refined by clinicians in the research
team.
Antidepressants including mirtazapine: individual
products were identified by searching by generic and
brand names in the product dictionary; categories
are then based on the British National Formulary
(BNF)(12) chapters.
Other medication code lists were based on the
recorded BNF chapters: antipsychotics (chapters
4.2.1 and 4.2.2), anxiolytic medications (chapter
4.1.2), hypnotic agents (chapter 4.1.1), NSAIDs
(chapter 10.1.1), statins (chapter 2.12.4), and
opioids (chapter 4.7.2).
Causes of death codes are based on ONS short list
of cause of death(30). ICD-10 codes for pre-
specified causes of interest are C00-C97 (malignant
neoplasms); I00-I99 (diseases of the circulatory
system); X60-X84, Y10-Y34 (intentional self-harm/
event of undetermined intent). The ONS short list will
be used to categorise additional causes of death in
the dataset.
For depression, a new list created by combining
Read code lists from three sources: the Quality and
Outcomes Framework depression cluster (QOF v38),
a list published by John et al(31), and a composite
list published by Carreira et al(32). In creating the list
we favoured specificity over sensitivity. First we
selected all codes included in the QOF cluster plus
any equivalent codes in the other list. From these,
we retained only the codes most specific to major
depression, dropping codes with additional mental
health conditions (e.g. “bipolar affective disorder,
now depressed”).
Palliative/end-of-life care: a new Read code list was
developed by the study team.
Self-harm: the current Read code list is based on
codes used by Carr et al (33) and Coupland et al(4).
ICD-10 codes for intentional self-harm/event of
undetermined intent (X60-X84, Y10-Y34) will be
used to find records in the HES data. These code
lists will be refined to meet the definition of near-
fatal deliberate self-harm described in Douglas et
al(26).
O. Data/ Statistical Analysis
1. Summary of baseline characteristics of patients
according to exposure group. Continuous
variables will be summarised using the median
and inter-quartile range. Categorical variables
will be summarised using counts and
percentages. The comparison groups will be
compared to the mirtazapine-switch group using
appropriate difference tests (chi-squared or
Mann-Whitney U tests).
2. Length of follow-up and reasons for end of
follow-up (e.g. outcome, stopping the drug of
interest, starting a new antidepressant) for each
of the exposure groups will be summarised.
3. Tabulation of the most frequent causes of death
according to exposure group.
4. Calculation of mortality/incidence rates for the
different exposure groups. These rates will be
age-sex standardised to the whole study
population. 95% confidence intervals will be
reported. Mortality/incidence rates will be
calculated for all causes of death, the pre-
specified causes of death, the most common
causes of death identified in step 2, and
suicide/near-fatal deliberate self-harm.
5. Missing values will be imputed (Section Q) and
propensity scores estimated for each of the
imputed datasets. The analyses will be run on
each of the imputed datasets, accounting for
each propensity score, before the results are
combined (the 'within' approach described by
Granger et al.(34)). Propensity scores will be
generated using a multinomial regression model
including the listed covariates (potential
confounding variables and risk factors for the
outcome). Appropriate model diagnostics will be
performed to ensure correct specification of the
propensity score and to evaluate the overlap of
the distribution between exposed and
groups(35). The inverse probability of treatment
weighting will be used to account for propensity
scores in the outcome models(36).
6. The risk of all-cause mortality associated with
exposure to mirtazapine vs. the comparator
antidepressants will be estimated using Cox
regression. The outcome will be time to death,
censoring when patients leave the cohort. A
simple model adjusting for age and sex will be
performed, followed by a model adjusting for
propensity scores. The proportional-hazards
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assumption will be tested for all models and
appropriate adjustments made where
necessary.
7. Cause-specific mortality will be studied using
Fine-Gray regression to account for competing
risks. The steps described in step 5 will be
repeated for this analysis.
8. Fine-Gray regression will be used to study the
risk of suicide/near-fatal deliberate self-harm,
including death from another cause as a
competing risk. The steps described in step 5
will be repeated for this analysis.
9. The effect of antidepressant dose will be
explored for starting dose and median dose, for
example by including dose as a covariate or
stratifying according to high/low starting dose.
10. As mentioned in Section H, we plan to repeat the
study using the QResearch database, given
appropriate approvals. The data preparation and
analysis will be repeated as closely as possible
and, if appropriate, results will be combined
using meta-analysis techniques as in previous
studies (e.g. Vinogradova et al. 2019 (23)).
Sensitivity analyses
Sensitivity analyses excluding patients with a prior
record for palliative/end-of-life care, near-fatal
deliberate self-harm, bipolar disorder, or
schizophrenia will be performed.
All-cause mortality rates and age-sex-adjusted Cox
regression models will be repeated after a) excluding
patients who have a record of palliative/end-of-life
care prior to index date, and b) excluding patients
with a record of self-harm prior to index date.
Subgroup analyses will be performed including
those aged 18-64 years and those aged 65-99 years
at index date.
The analyses will be repeated using a shorter risk
carry-over period (30 days after prescription stop
date). The longer carry-over period in the main study
(6 months) is included to allow for potential longer-
term effects of antidepressants, such as weight
gain, but may introduce misclassification bias. The
30-day carry-over period will reflect the immediate
effects of the drug and shorter-term withdrawal
effects.
Analyses will also be repeated after restricting the
maximum follow-up length to one year after index
date. It is possible the antidepressants may have
different tolerability and effectiveness in the study
cohort, leading to systematic differences in how long
patients persist on the different drugs.
If numbers allow, we will investigate possible drug
interactions within the augmented treatment group
by further grouping patients according to the initial
SSRI and comparing outcome rates.
Multiple testing
A significance level of 0.05 will be used throughout
the analyses. Where possible, 95% confidence
intervals will be reported alongside estimates. The
significance level will be made clear in publications
and the results interpreted with appropriate caution.
Disclosure control
Disclosure control techniques recommended by the
ONS will be used to minimise the risk of re-
identification. Minimum cell counts of 5 will be used.
P. Plan for Addressing Confounding
Propensity score adjustment will be used to address
confounding, as described in Section O. The study
population will also be restricted to patients with a
depression Read code with similar antidepressant
treatment histories, reducing the risk of indication
biases. Although imperfect, this step will reduce the
level of unmeasured variation by making the cohort
members more similar at baseline(37).
Q. Plans for Addressing Missing Data
Multiple imputation by chained equations will be
used to impute missing values for baseline
covariates (body mass index, ethnicity, socio-
economic status, alcohol use, smoking status,
depression severity). Twenty datasets will be
imputed and the results will be combined using
Rubin’s rules. All variables included in the propensity
score models and outcome models, including
survival time, death, and cause of death, will be
included in the imputation models. Drug exposure
and medical condition variables will be assumed not
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present if not recorded. The amount of missing data
will be reported in the study outputs.
R. Patient and Public Involvement
The study team includes two patient and public
involvement (PPI) representatives from the
MindTech Involvement team
(https://www.mindtech.org.uk/involvement), a
group of individuals with lived experience of mental
health conditions. The PPI representatives have
helped develop the protocol and will attend project
meetings and additional meetings throughout the
analysis. The project will therefore have patient
representation in study design, analysis,
interpretation, and dissemination of results
(including co-authorship of papers). We will also
discuss the progress and results of the study at
meetings of the Involvement Team.
S. Plans for Disseminating Study Results
We will publish the study in a peer-reviewed journal
article and follow the reporting guidelines of the
RECORD statement(38,39) (an extension of the
STROBE guidelines). We will submit abstracts for
presentation at conferences.
T. Possible Limitations
There is a risk of unmeasured confounding,
confounding by indication, and channelling bias in
this study. We attempt to address this in part by
restricting the study population to those with a Read
code for depression, starting follow-up at the first
antidepressant switch (or addition, for mirtazapine),
and calculating propensity scores to account for
systematic differences between exposure groups at
baseline. This will reduce some of the heterogeneity
within the population and ensure groups are more
similar. However, the possibility of unmeasured
confounding will still be present. We will
acknowledge this when interpreting the results of
the study.
Restricting the study population will reduce the
generalisability of the findings. For instance, we are
restricting the cohort to patients with a diagnosis of
depression first prescribed antidepressants after
the age of 18 years old. As the risk of confounding is
high, we have focused on reducing the potential
impact of this at the cost of generalisability. As major
depression is the only licensed indication for
mirtazapine, and mirtazapine is not licensed for use
in under 18 year-olds, we may not in fact exclude
many patients exposed to our main exposure of
interest. We will quantify the numbers of patients
dropped at each stage of cohort creation and
discuss generalisability in our study outputs.
There is likely to be measurement error/
misclassification in our exposure variable. We are
using prescriptions as a proxy for drug use. Non-
adherence is a recognised problem for many
prescription medicines. Furthermore it is possible
antidepressants are prescribed in secondary care,
thus we may underestimate true exposure. The
likelihood of this is difficult to quantify, although in
adult patients it is probable the majority of
antidepressants are initiated in primary care, or
continued in primary care if initiated in secondary
care. These errors may introduce misclassification
bias, the direction of which is difficult to predict. This
problem affects all pharmacoepidemiology studies
using routine data and will be acknowledged and
discussed in study outputs.
The study may lack power if the number of events is
low, for instance for some specific causes of death.
We will present confidence intervals for estimates
and discuss the possible impact during
interpretation of results.
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Appendix 1 - Code Lists
The preliminary code lists submitted with the protocol are available on request from the authors. The final code
lists will be shared as part of future publications. Key resources used to develop code lists include the CALIBER
phenotyping resource (https://www.caliberresearch.org/portal/phenotypes/chronological-map) and the
ClinicalCodes repository (https://clinicalcodes.rss.mhs.man.ac.uk/).
Appendix 2 - Time Windows
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